Urine Glycoprotein Profile Reveals Novel Markers for Chronic Kidney Disease by Vivekanandan-Giri, Anuradha et al.
Hindawi Publishing Corporation
International Journal of Proteomics
Volume 2011, Article ID 214715, 18 pages
doi:10.1155/2011/214715
Research Article
UrineGlycoproteinProﬁle Reveals Novel Markers for
ChronicKidneyDisease
AnuradhaVivekanandan-Giri,1 Jessica L.Slocum,1 CarolynL. Buller,1
VenkateshaBasrur,2 Wenjun Ju,1 Rodica Pop-Busui,3 DavidM.Lubman,2,4,5
Matthias Kretzler,1,4 andSubramaniamPennathur1,4
1Division of Nephrology, University of Michigan, Ann Arbor, MI 48105, USA
2Department of Pathology, University of Michigan, Ann Arbor, MI 48105, USA
3Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan,
Ann Arbor, MI 48105, USA
4Department of Computational Medicine and Biology, University of Michigan, Ann Arbor, MI 48105, USA
5Department of Surgery, University of Michigan, Ann Arbor, MI 48105, USA
Correspondence should be addressed to Subramaniam Pennathur, spennath@umich.edu
Received 30 June 2011; Accepted 30 July 2011
Academic Editor: David E. Misek
Copyright © 2011 Anuradha Vivekanandan-Giri et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Chronic kidney disease (CKD) is a signiﬁcant public health problem, and progression to end-stage renal disease leads to
dramatic increases in morbidity and mortality. The mechanisms underlying progression of disease are poorly deﬁned, and current
noninvasivemarkersincompletelycorrelatewithdiseaseprogression.Therefore,thereisagreatneedfordiscoveringnovelmarkers
for CKD. We utilized a glycoproteomic proﬁling approach to test the hypothesis that the urinary glycoproteome proﬁle from
subjects with CKD would be distinct from healthy controls. N-linked glycoproteins were isolated and enriched from the urine
of healthy controls and subjects with CKD. This strategy identiﬁed several diﬀerentially expressed proteins in CKD, including a
diversearrayofproteinswithendopeptidaseinhibitoractivity,proteinbindingfunctions,andacute-phase/immune-stressresponse
activitysupportingtheproposalthatinﬂammationmayplayacentralroleinCKD.Additionally,severaloftheseproteinshavebeen
previously linked to kidney disease implicating a mechanistic role in disease pathogenesis. Collectively, our observations suggest
that the human urinary glycoproteome may serve as a discovery source for novel mechanism-based biomarkers of CKD.
1.Introduction
Chronic kidney disease (CKD) aﬀects approximately 11% of
the US population with over 100,000 individuals progressing
to end-stage renal disease (ESRD) annually [1, 2]. Despite
this signiﬁcant and growing public health problem, it
remains diﬃcult to predict which individuals will progress
to ESRD. As ESRD carries a substantial increase in morbidity
and mortality, it is critical to identify this high-risk patient
populationthatwouldmostbeneﬁtfromearlyandaggressive
therapy.
Current strategies for predicting CKD progression are
limited. Pathologic examination of renal tissue provides val-
uable information on degree of interstitial ﬁbrosis and
predilection for ESRD. However, renal biopsy is invasive
with a limited role for longitudinal followup. Quantitative
measures of proteinuria have long been used as nonin-
vasive markers of CKD progression [3], yet these largely
albumin-based methods detect nonselective proteinuria and
incompletely correlate with disease. With recent advances
in high through-put technology and mass spectrometry
techniques,urineproteomicinvestigationisanattractivetool
in the pursuit for noninvasive and speciﬁc markers of CKD
progression [4, 5].
Numerous investigators have successfully applied broad-
scale urine proteomic strategies to kidney disease. The urine2 International Journal of Proteomics
Table 1: Patient characteristics of study subjects.
Variable Healthy control (n = 6) CKD (n = 6) P
Age (years) 46.3 (13.5) 47.2 (14.2) 0.92
Sex (male/female) 2/4 2/4 1.00
Body mass index (kg/m2) 24.3 (3.0) 30.5 (4.8) 0.02
Serum creatinine (mg/dL) 0.85 (0.16) 1.75 (1.09) 0.07
eGFR (mL/min)∗ 83.0 (15.0) 52.0 (27.4) 0.05
Protein/creatinine ratio 0.03 (0.02) 2.15 (1.44) 0.01
All data expressed as mean ± SD.
eGFR estimated glomerular ﬁltration rate.
∗eGFR calculated from Modiﬁcation of Diet in Renal Disease formula.
proteomepredictsnephropathyanddeclineinrenalfunction
in diabetic subjects [6, 7]. It also correlates with early
changes of focal segmental nephrosclerosis [8], can identify
IgA nephropathy and renal allograft rejection [9, 10], and
predicts treatment response and disease activity in nephrotic
syndrome and lupus nephritis [11, 12]. Despite these
advances,analysisoftheentireurineproteomeisparticularly
diﬃcultin CKD. With disruption of theglomerularﬁltration
barrier and leakage of abundant plasma proteins into the
urine, a nonselective, largely albumin predominant, pattern
often results [13]. To overcome this, methods to increase the
detection of low-abundance proteins have been developed
to provide disease speciﬁcity and clinical relevance of
urine proﬁling and to mechanistically understand factors
inﬂuencing disease progression.
Glycoprotein enrichment techniques allow depletion of
albumin and other abundant plasma proteins while provid-
ing a more thorough analysis of a subfraction of the urine
p r o t e o m e .A sg l y c o s y l a t e dp r o t e i n sa r ec r i t i c a lf o rc e l l u l a r
interactions and signaling cascades, disease states are likely
to cause early and speciﬁc alterations in urinary glycoprotein
excretion. Indeed, glycoproteins are now important markers
ofautoimmunityandmalignancy[14,15].Morerecently,the
plasma glycoproteome has been used to predict nephropathy
in diabetic subjects [16]. Despite this promising role as a
noninvasive and speciﬁc biomarker of disease, little is known
about the urinary glycoproteome in CKD.
We hypothesized that the urinary glycoproteome would
be altered in CKD compared to healthy controls and
that speciﬁc glycoprotein alterations might be useful in
predicting CKD progression. The overall goal of this study
was to perform an initial exploratory analysis of the urine
glycoproteins in patients with CKD compared to healthy
controls.Wepresentacomprehensiveproﬁlingoftheurinary
glycoproteome in control and CKD subjects utilizing a
hydrazide enrichment technique combined with tandem
mass spectrometry identiﬁcation of the glycoproteins.
2. Methods
2.1. Sample Collection and Processing. Clean catch urine
samples were obtained from six CKD subjects and six
age-matched healthy controls following written informed
consentapprovedbytheUniversityofMichiganInstitutional
R e v i e wB o a r d .S a m p l e sw e r es t o r e da t−80◦C and thawed
Control CKD
08 35 79
Figure 1: Venn diagram of the total urinary glycoproteins detected
in healthy controls and CKD subjects. Tryptic digests of urine
glycoproteins were subjected to LC-ESI-MS/MS analysis, and the
proteins were identiﬁed as described in Section 2. 35 proteins were
unique to healthy control subjects while 8 proteins were unique to
subjects with CKD. 79 proteins were present in both groups.
immediately prior to proteomic analysis. An initial 5000g
centrifugation was performed at 4◦Cf o r1 0m i n u t e st o
remove cellular debris. Approximately, 30–50mL healthy
controlsamplesand1-2mLCKD sampleswereconcentrated
using a 3kDa ﬁlter cut-oﬀ membrane (Vivaspin 3kDa
MWCO, GE healthcare, Buckinghamshire, UK and Amicon
ultra 0.5mL, Millipore, Ireland resp.). As CKD subjects
had higher urinary protein content (Table 1), the processed
volumes were lower.
Urine protein concentration was determined using
Coomassie Protein Assay Reagent with BSA standard
(Thermo Scientiﬁc, Rockford, Illinois). 200μgo fc o n c e n -
trated protein were utilized for downstream processing.
Protein samples were exchanged into 50mM ammonium
bicarbonate buﬀer (pH 7.4). Urine creatinine concentration
was determined by tandem mass spectrometry (MS/MS)
as described previously by our group [17]. To determine
the level of creatinine, a known amount of [2H3]creatinine
was spiked into each sample. A full-scan mass spectrum
revealed molecular ions of m/z 114 and 117 for authentic
creatinine and [2H3]creatinine, respectively. The transitions
of the m/z 114 to 44 and m/z 117 to 47 were monitored
in multiple-reaction monitoring mode for authentic and
[2H3]creatinine, respectively, utilizing an Agilent Technolo-
gies (New Castle, DE) 6410 Triple Quadrupole mass spec-
trometer system, equipped with an Agilent 1200 series HPLCInternational Journal of Proteomics 3
Table 2: Urinary glycoproteins unique to CKD or healthy control subjects.
Unique proteins in healthy controls Unique proteins in CKD
70kDa lysosomal alpha-glucosidase (GAA) Antithrombin-III (SERPINC1)
Alpha-1B-glycoprotein (A1BG) Complement factor H-related 1 (CFHR1)
Basigin (BSG) Desmoglein-2 (DSG2)
Beta-galactosidase (GLB1) Lumican (LUM)
Beta-sarcoglycan (SGCB) Lymphatic vessel endothelial hyaluronic acid receptor 1 (LYVE1)
Butyrophilin (BTN2A1) Pigment epithelium-derived factor (SERPINF1)
Carboxypeptidase M (CPM) Thyroxine-binding globulin (SERPINA7)
CD276 antigen (CD276) Zinc-alpha-2-glycoprotein (AZP1)
Complement component C4B (C4B)
Cubilin (CUBN)
Colony stimulating factor 1 (macrophage) (CSF1)
Delta and notch-like epidermal growth factor-related receptor (DNER)
Desmocollin-2 (DSC2)
Desmoglein-1 (DSG1)
Epidermal growth factor (EGFR)
Secreted frizzled-related protein-4 (SFRP4)
Fibronectin 1 (FN1)
Folate receptor alpha (FOLR1)
Golgi phosphoprotein 2 (GOLPH2)
Glutamyl aminopeptidase (ENPEP)
Hepatitis B virus receptor binding protein (Q6PYX1)
Hepatic asialoglycoprotein receptor 1 transcript variant b (ASGR1)
Heparan sulfate proteoglycan 2 (HSPG2)
Intercellular adhesion molecule 1 (ICAM1)
Kallikrein-1 (KLK1)
Kallikrein 3 (APS)
Lysosomal alpha-glucosidase (GAA)
Lysosomal-associated membrane protein 2 (LAMP2)
Maltase-glucoamylase (MGAM)
Microﬁbril-associated glycoprotein 4 (MFAP4)
Mucin-6 (MUC6)
Neuronal pentraxin receptor (NPTXR)
Neuropilin and tolloid-like protein 1 (NETO1)
Probable serine carboxypeptidase (CPVL)
Sex hormone binding globulin (SHBG)
system.Thecreatinineconcentrationintheurinesamplewas
determined by comparing the peak areas for authentic and
[2H3]creatinine for the above transitions.
2.2. Glycoprotein Separation and Enrichment. In order to
assess recovery following the enrichment procedure, 5μgo f
invertase from Saccharomyces cerevisiae (Sigma, St. Louis,
MO) was spiked into 200μg of protein in every sample.
Glycoproteins were enriched from urinary proteins utilizing
the hydrazide resin capture protocol as described previ-
ously by Zhang et al. [18]. Brieﬂy, samples were oxidized
with 10mM sodium metaperiodate then incubated with
hydrazide resin overnight at room temperature. Samples
were then centrifuged at 3000g for 2 minutes and the resin
was washed successively with equal volumes 50mM ammo-
nium bicarbonate buﬀer (pH 7.4; Buﬀer A) supplemented
with 8M urea, followed by Buﬀer A alone and then water.
The beads were resuspended in water, and the protein was
reduced with 5mm DTT followed by alkylation with 15mM
iodoacetamide. Trypsin (sequencing grade modiﬁed trypsin,
Promega Corporation, Madison, WI) at 1:20μgr a t i ow a s
added to the samples and incubated overnight at 37◦Cf o r
digestion. Following digestion, the beads were centrifuged
at 3000g for 2 minutes and the resin was then washed suc-
cessively with 1.5M NaCl, 80% acetonitrile, 100% methanol,
andBuﬀerA.TheresinwasthenresuspendedinBuﬀerAand
incubated with 5 units of PNGaseF (New England Biolabs,
Ipswich,MA)overnightat37◦Cforglycopeptiderelease.The
glycopeptideswerecleanedusingareversephasecolumnand4 International Journal of Proteomics
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Figure 2: Mass Spectra of glycopeptides derived from Zinc alpha 2 Glycoprotein (a) and Golgi phosphoprotein (b) in CKD urine.
Tryptic digests of urine glycoproteins were subjected to LC-ESI-MS/MS analysis as described in Section 2. The mass spectra of peptides
DIVEYYNDSNGSHVLQG from zinc alpha 2 glycoprotein which is upregulated (a) and those of peptide AVLVNNITTGER from Golgi
phosphoprotein which is signiﬁcantly downregulated in CKD subjects (b) are shown. The N-linked glycosylation site of each peptide is
depicted in red.
eluted with 50% acetonitrile/0.1% TFA followed by elution
with 80% acetonitrile/0.1% TFA. The peptides were then
dried at 60◦Ci nav a c u u mc e n t r i f u g ea n ds t o r e df o rm a s s
spectrometric analysis.
2.3. Liquid Chromatography Electrospray Ionization (ESI/LC)
MS/MS Analysis. Peptide samples were resuspended in 0.1%
formic acid and loaded onto an in-house packed reverse
phase separation column (0.075×100mm, MAGIC C18 AQ
particles, 5μm, Michrom Bioresources). The peptides were
separated on a 1% acetic acid/acetonitrile gradient system
(5–50% acetonitrile for 75min, followed by a 10min 95%
acetonitrile wash) at a ﬂow rate of ∼300nl/min. Peptides
were directly sprayed onto the MS using a nanospray
source. An LTQ Orbitrap XL (Thermo Fisher Scientiﬁc,
Waltham, MA) was run in automatic mode collecting a
high resolution MS scan (FWHM 30,000) followed by data-
dependent acquisition of MS/MS scans on the 9 most intense
ions (relative collision energy ∼35%). Dynamic exclusion
was set to collect 2MS/MS scans on each ion and exclude it
for an additional 2min. Charge state screening was enabled
to exclude +1 and undetermined charge states.
2.4. Data Processing and Statistical Analysis. The Human
UniProt database (Release 2011-5) was appended with a
reverse database, a common contaminant list, and yeast
invertase. Raw ﬁles were converted to mzXML format and
searched against the database using X!Tandem with a k-
score plug-in, an open-source search engine developed by
the Global Proteome Machine (http://www.thegpm.org/).
The search parameters were as follows: (1) precursor
mass tolerance window of 100ppm and fragment massInternational Journal of Proteomics 5
Table 3: Glycoproteins identiﬁed with peptides carrying NxS/T motif.
No. Protein Charge state Peptide sequence with NxS/T motif
1 155kDa platelet multimerin
(MMRN1)
2+
2+
LQN[115]LTLPTN[115]ASIK
FNPGAESVVLSN[115]STLK
2 70kDa lysosomal
alpha-glucosidase (GAA)
2+
2+
GVFITN[115]ETGQPLIGK
LEN[115]LSSSEM[147]GYTATLTR
3 Afamin (AFAM) 2+
2+/3+
DIENFN[115]STQK
YAEDKFN[115]ETTEK
4 Aminopeptidase N (AMPN) 3+
2+
KLN[115]YTLSQGHR
N[115]ATLVNEADKLR
5 Attractin (ATRN) 2+ IDSTGN[115]VTNELR
6 Apolipoprotein D
(APO D)
2+/3+
2+
ADGTVNQIEGEATPVN[115]LTEPAK
C[160]IQAN[115]YSLM[147]EN[115]GK
7 Apolipoprotein F (APO F) 2+ Q[111]GGVN[115]ATQVLIQHLR
8 Apolipoprotein J (APO J)
2+
2+/3+
3+
3+
LAN[115]LTQGEDQYYLR
EDALN[115]ETRESETK
M[147]LN[115]TSSLLEQLNEQFNWVSR
EIRHN[115]STGC160LR
9 Alpha-1-antichymotrypsin
(AACT)
3+/4+
3+/4+
2+/3+
2+/3+
GLKFN[115]LTETSEAEIHQSFQHLLR
YTGN[115]ASALFILPDQDKM[147]EEVEAM[147]LLPETLKR
TLN[115]QSSDELQLSM[147]GNAM[147]FVK
KLIN[115]DYVKN[115]GTR
10 Alpha-2-HS-glycoprotein
(FETUA)
2+/3+
2+/3+
AALAAFNAQNN[115]GSNFQLEEISR
KVC[160]QDC[160]PLLAPLN[115]DTR
11 Alpha-1-acid
glycoprotein 1 (ORM1)
2+/3+
3+
3+/4+
QDQC[160]IYN[115]TTYLNVQR
SVQEIQATFFYFTPN[115]KTEDTIFLR
N[115]EEYN[115]KSVQEIQATFFYFTPN[115]KTEDTIFLR
12 Alpha-1-acid
glycoprotein 2 (ORM2)
2+/3+
3+
QNQC[160]FYN[115]SSYLNVQR
SVQEIQATFFYFTPN[115]KTEDTIFLR
13 Alpha-1B-glycoprotein (A1BG) 3+/4+ EGDHEFLEVPEAQEDVEATFPVHQPGN[115]YSC[160]SYR
14 Antithrombin-III (SERPINC1) 2+/3+
2+
LGAC[160]N[115]DTLQQLM[147]EVFKFDTISEK
SLTFN[115]ETYQDISELVYGAK
15 Basigin (BSG) 3+
3+
ITDSEDKALM[147]N[115]GSESR
ILLTC[160]SLN[115]DSATEVTGHR
16 Beta-galactosidase (GLB1) 2+ NNVITLN[115]ITGK
17 Beta-sarcoglycan (SGCB) 2+ ITSN[115]ATSDLNIK
18 Biotinidase (BTD) 2+/3+
2+/3+
NPVGLIGAEN[115]ATGETDPSHSK
DVQIIVFPEDGIHGFN[115]FTR
19
Butyrophilin,
subfamily 2, member A1
(BTN2A1)
2+ GSVALVIHN[115]ITAQEN[115]GTYR
20 Cathepsin D heavy chain (CTSD) 2+ GSLSYLN[115]VTR
21 Cathepsin L (CTSL) 3+ YSVAN[115]DTGFVDIPKQEK
22 Carboxypeptidase
B2 (CBPB2) 2+/3+ QVHFFVN[115]ASDVDNVK
23 Carboxypeptidase
M( C B P M )
2+
4+
NFPDAFEYNN[115]VSR
TVAQN[115]YSSVTHLHSIGK
24 Calcium binding protein 39
(CAB39) 2+ HN[115]FTIM[147]TK
25 CD276 antigen (CD276) 2+ VVLGAN[115]GTYSC[160]LVR
26 CD163 antigen (CD163) 2+ APGWAN[115]SSAGSGR
27 CD44 protein (CD44) 2+ AFN[115]STLPTM[147]AQM[147]EK
28 CD7 antigen (CD7) 3+ GRIDFSGSQDN[115]LTITM[147]HR6 International Journal of Proteomics
Table 3: Continued.
No. Protein Charge state Peptide sequence with NxS/T motif
29 Cell adhesion molecule 1
(CADM1)
2+
2+
VSLTN[115]VSISDEGR
FQLLN[115]FSSSELK
30 Ceruloplasmin (CP)
2+/3+
3+/4+
2+
EHEGAIYPDN[115]TTDFQR
ELHHLQEQN[115]VSNAFLDKGEFYIGSK
EN[115]LTAPGSDSAVFFEQGTTR
31 Complement component C4B
(C4B) 2+ GLN[115]VTLSSTGR
32 Complement factor H (CFH) 3+ IPC[160]SQPPQIEHGTIN[115]SSR
33 Complement factor H-related 1
(CFHR1) 2+ LQNNENN[115]ISC[160]VER
34 Complement
factor I (CFI) 2+ FLNN[115]GTC[160]TAEGK
35 Cubilin (CUBN) 2+
2+
LC[160]SSVN[115]VSNEIK
AGFN[115]ASFHK
36 Corticosteroid-binding globulin
(SERPINA6)
2+
3+
AQLLQGLGFN[115]LTER
AVLQLNEEGVDTAGSTGVTLN[115]LTSKPIILR
37 Colony stimulating factor 1
(macrophage) (CSF1) 2+ VKNVFN[115]ETK
38
Delta and notch-like epidermal
growth factor-related receptor
(DNER)
2+ LVSFEVPQN[115]TSVK
39 Desmocollin-2 (DSC2) 2+
2+
LKAIN[115]DTAAR
AN[115]YTILK
40 Desmoglein-1 (DSC1) 2+ DYNTKN[115]GTIK
41 Desmoglein-2 (DSG2) 2+
2+
IN[115]ATDADEPNTLNSK
YVQN[115]GTYTVK
42 DNA ligase 4 (LIG4) 2+ APN[115]LTNVNK
43 Dual speciﬁcity protein
phosphatase CDC14B (CDC14B) 2+ NHN[115]VTTIIR
44 Epidermal growth factor (EGF) 2+ GN[115]NSHILLSALK
45
Epididymis secretory sperm
binding protein Li 44a
(SERPINA1)
2+/3+/4+
3+/4+
YLGN[115]ATAIFFLPDEGKLQHLENELTHDIITK
ADTHDEILEGLNFN[115]LTEIPEAQIHEGFQELLR
46 Extracellular link domain
containing 1 (XLKD1) 2+/3+ KANQQLN[115]FTEAK
47 Fibrillin 1 (FBN1) 2+ TAIFAFN[115]ISHVSNK
48 Fibrinopeptide A (FGA) 2+ M[147]DGSLNFN[115]RT
49
Fibronectin type III
domain-containing protein 5
(FNDC5)
2+ FIQEVN[115]TTTR
50 Frizzled protein 4 (FRP4) 2+ ISM[147]C[160]QNLGYN[115]VTK
51 Fibronectin 1 (FN1) 3+ DQC[160]IVDDITYNVN[115]DTFHK
52 Folate receptor alpha (FOLR1) 2+ GWN[115]WTSGFNK
53 Galectin-3-binding protein
(LGALS3BP)
2+
2+
2+
2+
ALGFEN[115]ATQALGR
AAIPSALDTN[115]SSK
GLN[115]LTEDTYKPR
TVIRPFYLTN[115]SSGVD
54 Glutaminyl-peptide
cyclotransferase (QPCT)
2+/3+
3+/4+
NYHQPAILN[115]SSALR
YFQN[115]YSYGGVIQDDHIPFLR
55 Golgi phosphoprotein 2
(GOLPH2)
3+
1+/2+
LQQDVLQFQKN[115]QTNLER
AVLVN[115]N[115]ITTGERInternational Journal of Proteomics 7
Table 3: Continued.
No. Protein Charge state Peptide sequence with NxS/T motif
56 Glutamyl aminopeptidase
(ENPEP) 2+ HTAEYAAN[115]ITK
57 Haptoglobin beta
chain (HP)
2+/3+
3+/4+
2+/3+/4+
3+
VVLHPN[115]YSQVDIGLIK
MVSHHN[115]LTTGATLINEQWLLTTAK
NLFLN[115]HSEN[115]ATAKDIAPTLTLYVGKK
Q[111]LVEIEKVVLHPN[115]YSQVDIGLIK
58 HEG homolog 1 (HEG1) 2+ SYSESSSTSSSESLN[115]SSAPR
59 Hemopexin (HPX) 3+/4+
2+
GHGHRN[115]GTGHGN[115]STHHGPEYM[147]R
ALPQPQN[115]VTSLLGC[160]TH
60 Hepatitis B virus receptor
binding protein (Q6YPX1) 2+ EEQYN[115]STYR
61
Hepatic asialoglycoprotein
receptor 1 transcript variant b
(ASGR1)
2+ ETFSN[115]FTASTEAQVK
62 Heparan sulfate proteoglycan 2
(HSPG2) 2+ ALVN[115]FTR
63 Ig alpha-1 chain C
region (IGHA1) 3+ LAGKPTHVN[115]VSVVM[147]AEVDGTC[160]Y
64 Ig gamma-1 chain C region
(IGHG1)
2+
2+/3+
EEQYN[115]STYR
TKPREEQYN[115]STYR
65 Ig gamma-2 chain C region
(IGHG2)
2+
2+/3+
EEQFN[115]STFR
TKPREEQFN[115]STFR
66 Ig gamma-4 chain C region
(IGHG4)
2+
2+/3+
EEQFN[115]STFR
TKPREEQFN[115]STFR
67 Ig mu chain C
region (IGHM) 2+ YKN[115]NSDISSTR
68 Inducible T-cell co-stimulator
ligand (ICOSLG) 2+ TVVTYHIPQN[115]SSLENVDSR
69
Insulin-like growth
factor-binding
protein 3 (IGFBP3)
2+ GLC[160]VN[115]ASAVSR
70 Intercellular adhesion molecule 1
(ICAM1)
2
2+
LNPTVTYGN[115]DSFSAK
AN[115]LTVVLLR
71 Intercellular adhesion molecule 2
(ICAM2) 2+ GN[115]ETLHYETFGK
72 Kallikrein-1 (KLK1) 4+ HNLFDDEN[115]TAQFVHVSESFPHPGFN[115]M[147]SLLEN[115]HTR
73 KALLIKREIN-2 (KLK2) 2+ N[115]KSVILLGR
74 Kininogen 1 (KNG1)
2+
2+
3+/4+
2+
LNAENN[115]ATFYFK
ITYSIVQTN[115]C[160]SK
HGIQYFNN[115]NTQHSSLFTLNEVKR
YNSQN[115]QSNNQFVLYR
75 Leucine-rich
alpha-2-glycoprotein (LRG1)
2+
2+/3+
MFSQN[115]DTR
KLPPGLLAN[115]FTLLR
76
Leukocyte-associated
immunoglobulin-like receptor 1
(LAIR1)
2+/3+ STYN[115]DTEDVSQASPSESEAR
77 Lumican (LUM) 3+ KLHINHNN[115]LTESVGPLPK
78 Lysosomal acid phosphatase
(ACP2) 2+ YEQLQN[115]ETR
79 Lysosomal alpha-glucosidase
(GAA)
2+
2+
GVFITN[115]ETGQPLIGK
LEN[115]LSSSEM[147]GYTATLTR
80 Lysosome-associated membrane
glycoprotein 1 (LAMP1) 2+ GHTLTLN[115]FTR8 International Journal of Proteomics
Table 3: Continued.
No. Protein Charge state Peptide sequence with NxS/T motif
81 Lysosomal-associated membrane
protein 2, (LAMP2) 2+ VASVININPN[115]TTHSTGSC[160]R
82
Lymphatic vessel endothelial
hyaluronic acid receptor 1
(XLKD1)
2+ ANQQLN[115]FTEAK
83 Lysyl oxidase (LOX) 3+
3+
AEN[115]QTAPGEVPALSNLRPPSR
RDPGAAVPGAAN[115]ASAQQPR
84 Major prion protein (PRNP) 2+ Q[111]HTVTTTTKGEN[115]FTETDVK
85 Membrane protein FAM174A
(FAM174A) 2+ GSEGGN[115]GSNPVAGLETDDHGGK
86 Maltase-glucoamylase (MGAM) 2+
2+
ILGM[147]EEPSN[115]VTVK
VILILDPAISGN[115]ETQPYPAFTR
87 Microﬁbril-associated
glycoprotein 4 (MFAP4) 2+ VDLEDFEN[115]NTAYAK
88 Monocyte diﬀerentiation antigen
CD14 2+ LRN[115]VSWATGR
89 Mucin-6 (MUC6) 2+ GC[160]M[147]AN[115]VTVTR
90 N-acetylglucosamine-6-
sulfatase (GNS)
2+
2+
YYN[115]YTLSIN[115]GK
TPMTN[115]SSIQFLDNAFR
91 N-acylsphingosine
amidohydrolase (ASAH1) 2+ TVLEN[115]STSYEEAK
92 Neuronal pentraxin receptor
(NPTXR) 2+ ALPGGADN[115]ASVASGAAASPGPQR
93 Neuropilin and tolloid-like
protein 1 (NETO1) 2+ HESEYN[115]TTR
94 Peptidase inhibitor 16 (PI16) 2+ SLPNFPN[115]TSATAN[115]ATGGR
95 Pigment epithelium-derived
factor (SERPINF1) 3+ VTQN[115]LTLIEESLTSEFIHDIDR
96
Plasma protease
C1 inhibitor
(SERPING1)
2+/3+
2+
3+
GVTSVSQIFHSPDLAIRDTFVN[115]ASR
VLSN[115]NSDANLELINTWVAK
VGQLQLSHN[115]LSLVILVPQNLK
97 Plasma serine protease inhibitor
(SERPINA5) 2+ VVGVPYQGN[115]ATALFILPSEGK
98 Platelet-derived growth factor
subunit B (PDGFB) 3+ LLHGDPGEEDGAELDLN[115]M[147]TR
99 Polytrophin (TROPH) 2+ N[115]N[115]VTEDIK
100 Probable G-protein coupled
receptor 116 (GPR116)
2+
2+
ANEQVVQSLN[115]QTYK
YEEQQLEIQN[115]SSR
101 Probable serine
carboxypeptidase (CPVL) 2+ Q[111]AIHVGN[115]QTFNDGTIVEK
102 Prosaposin (PSAP) 2+/3+ NLEKN[115]STKQEILAALEK
103 Prostaglandin D2 synthase
21kDa (PTGDS)
2+/3+
2+
SVVAPATDGGLN[115]LTSTFLR
WFSAGLASN[115]SSWLR
104 Prostatic acid phosphatase
(ACPP) 3+ FLN[115]ESYKHEQVYIR
105 Proteinase-activated receptor 1
(F2R) 2+ ATN[115]ATLDPR
106 Protein shisa-7 (SHISA7) 2+ LTGALTGGGGAASPGAN[115]GTR
107 RING ﬁnger protein 10 (RNF10) 2+ N[115]ESFN[115]N[115]QSRInternational Journal of Proteomics 9
Table 3: Continued.
No. Protein Charge state Peptide sequence with NxS/T motif
108 Secretory component (Polymeric
IG Receptor) (PIGR)
3+
2+
2+
2+
AN[115]LTNFPEN[115]GTFVVNIAQLSQDDSGR
Q[111]IGLYPVLVIDSSGYVNPN[115]YTGR
VPGN[115]VTAVLGETLK
YKCGLGIN[115]SR
109 Slit homolog 1 (SLIT1) 2+ LELN[115]GN[115]N[115]ITR
110 Sushi domain-containing protein
2 (SUSD2) 2+ SELVN[115]ETR
111 Sex hormone binding globulin
(SHBG) 2+ LDVDQALN[115]RT
112 Transferrin (TF) 2+/3+
2+/3+
Q[111]QQHLFGSN[115]VTDC[160]SGNFC[160]LFR
C[160]GLVPVLAENYN[115]KSDN[115]C[160]EDTPEAGYFAVAVVK
113 Thrombin heavy
chain (F2) 4+ YPHKPEIN[115]STTHPGADLQENFC[160]R
114 Tripeptidyl-peptidase I variant
(TPP1) 3+ FLSSSPHLPPSSYFN[115]ASGR
115 Tyrosine-protein kinase receptor
UFO (AXL)
2+
3+
SLHVPGLN[115]KT
N[115]GSQAFVHWQEPR
116 TIMP metallopeptidase inhibitor
1 (TIMP1)
2+
3+
FVGTPEVN[115]QTTLYQR
SHN[115]RSEEFLIAGK
117 Thyroxine-binding globulin
(SERPINA7) 2+ TLYETEVFSTDFSN[115]ISAAK
118 Trypstatin (AMBP) 2+/3+ SKWN[115]ITM[147]ESYVVHTNYDEYAIFLTK
119 Transmembrane protein 108
(TMEM108) 4+ KGAGN[115]SSRPVPPAPGGHSR
120 Uromodulin
(UMOD)
2+/3+
2+
2+/3+
Q[111]DFN[115]ITDISLLEHR
FALLMTNCYATPSSN[115]ATDPLK
CNTAAPMWLN[115]GTHPSSDEGIVSR
121 Vasorin (VASN) 2+ LHEITN[115]ETFR
122 Zinc-alpha-2-glycoprotein
(AZGP1)
2+/3+
3+/4+
2+
DIVEYYN[115]DSN[115]GSHVLQGR
AREDIFM[147]ETLKDIVEYYN[115]DSN[115]GSHVLQGR
FGCEIENN[115]RS
tolerance of 0.8Da; (2) allowing two missed cleav-
ages; (3) variable modiﬁcation: oxidation of methion-
ine (+15.9949Da), carbamidomethyl cysteine (57.0214Da),
and +0.9840Da, reﬂecting the conversion of asparagine
in the NxS/T motif to aspartate due to the release
of the N-linked glycopeptides from their oligosaccha-
rides. All proteins with a ProteinProphet probability of
greater than 0.9 were considered as positive identiﬁca-
tions [19]. Only proteins containing peptides with the
NxS/T sequence motif were included for statistical analy-
sis.
Baseline characteristics of the control and CKD subjects
were compared using Fisher’s exact test for categorical
variables and Student’s t-test for continuous variables. Data
is presented as means (±SD). Spectral counts for individ-
ual proteins were normalized to Saccharomyces cerevisiae
invertase and to urine creatinine content. Spectral counts
were compared across the two subject groups using the
nonparametric Mann-Whitney test, and P values were
adjusted for multiple comparisons using the False Discovery
Rate (FDR) with reported q-values. All statistical analyses
were performed with the use of SAS software, version 9.2.
2.5. Gene Ontology Analysis. Signiﬁcant proteins of inter-
est were analyzed using the Gene Ontology Database
(Gene Ontology Consortium, http://www.geneontology.org,
Princeton University, New Jersey, US; [20]). For a given
Gene Ontology (GO) category, the relative enrichment
of genes encoding the proteins detected in CKD relative
to all reference genes in that category were calculated
as previously described using GO Tools made available
by the Bioinformatics Group at the Lewis-Sigler Institute
(Princeton University, New Jersey, US; [21]). A cutoﬀ value
of P<0.01 was used to report a functional category
as signiﬁcantly overrepresented. To address the multiple
comparisons problem that arises when many processes are
evaluated simultaneously, the analysis included calculation
of the FDR [21]. To improve statistical conﬁdence in our
results, all enriched functional categories were required to be
signiﬁcant using both methods (P<0.01 and FDR < 0.05).
3. Results
3.1. Study Subject Characteristics. Urine was isolated from
six subjects with CKD and six age-matched healthy controls.10 International Journal of Proteomics
Baseline subject characteristics are provided in Table 1.T w o
important issues were considered with patient selection.
First, the etiology of CKD was chosen to be diverse. This
would ensure robustness of the putative markers as a CKD
marker rather than a disease-speciﬁc marker. Second, we
speciﬁcally targeted early Stage 3 CKD subjects to identify
early disease markers that would potentially indicate path-
ways dysregulated early in the course of disease. This might
oﬀer mechanistic insights into disease pathogenesis and
progression and have implications in therapeutic strategies.
The six subjects had biopsy-proven diabetic nephropathy,
lupus nephritis (n = 2), postacute tubular necrosis damage,
NSAID nephropathy, and membranoproliferative glomeru-
lonephritis, respectively. The mean estimated glomerular
ﬁltration rate (eGFR) was 83mL/min in control subjects and
52mL/min in CKD subjects.
3.2. Glycoprotein Spectral Count Normalization. Glycopro-
teins were extracted and enriched from the twelve urinary
samples. To account for variations in the glycoprotein
extraction eﬃciency, 5μg of the yeast protein invertase from
Saccharomyces cerevisiae was added to each sample prior to
extraction. After addition to the database, invertase spectral
count served as a surrogate marker for extraction eﬃciency
in each individual sample. Invertase spectral counts ranged
from 31 to 122 in the twelve samples with an average
spectral count of 86 (±31). Each sample was normalized
independently to the invertase spectral counts.
To account for intersubject urine concentration variabil-
ity, spectral counts were then normalized to urine creatinine
content. This provides standardization for urinary creatinine
excretion and concentration diﬀerences which can vary
with volume status, stress, diet, activity level, age, gender,
and overall health status [22]. Indeed, this normalization
is commonly followed in clinical practice where degree of
urinary protein is normalized to creatinine to obtain protein
excretion rates [23]. Final spectral counts were expressed per
mmol creatinine.
3.3. Urine Glycoproteome Is Altered in CKD. Urinary glyco-
proteins were isolated from six subjects with CKD and six
healthy controls using a hydrazide technique as described
in Section 2. A total of 122 glycoproteins were identiﬁed, of
which 35 proteins were unique to healthy control patients, 8
were unique to CKD subjects, and 79 were common proteins
in both groups (Figure 1, Table 2). Unique proteins to the
CKD group were Antithrombin-III (SERPINC1), Comple-
ment factor H-related 1 (CFHR1), Desmoglein-2 (DSG2),
Lumican (LUM), Lymphatic vessel endothelial hyaluronic
acid receptor 1 (LYVE1), Pigment epithelium-derived factor
(SERPINF1), Thyroxine-binding globulin (SERPINA7), and
Zinc-alpha-2-glycoprotein (AZP1).
Figure 2 displays MS spectra of two individual glycopep-
tides with glycosylation motifs which were altered in CKD
subjects. Zinc-alpha-2-glycoprotein is signiﬁcantly upregu-
lated in CKD (Figure 2(a)), while Golgi phosphoprotein is
signiﬁcantly downregulated in CKD (Figure 2(b)). Table 3
displays motifs and speciﬁc peptide modiﬁcations for all
unique 122 proteins. Proteins were only included if the
peptides contained the NxS/T motif.
To test if proteins were signiﬁcantly up- or downregu-
lated in CKD, normalized spectral counts from the 6CKD
subjectswerecomparedwiththosefromthehealthycontrols.
As sample size was small and spectral counts were not
normally distributed, comparisons were made with the
nonparametric Mann-Whitney test. As 122 proteins were
being simultaneously tested, the FDR and corresponding
q-values were determined to account for false positive
results. Table 4 displays 23 proteins which are diﬀerentially
expressed in CKD utilizing an uncorrected P value threshold
of less than 0.05. These proteins include 70kDa lysoso-
mal alpha-glucosidase (GAA), Apolipoprotein D (APOD),
Alpha-2-HS-glycoprotein chain B (FETUA), Alpha-1-acid
glycoprotein 1 (ORM1), Antithrombin-III (SERPINC1),
Beta-galactosidase (GLB1), Ceruloplasmin (CP), Cubilin
(CUBN), Epidermal growth factor (EGF), Epididymis secre-
tory sperm binding protein Li 44a (E9KL23), Galectin-
3-binding protein (LGALS3BP), Golgi phosphoprotein 2
(GOLPH2), Haptoglobin beta chain (HP), Ig gamma-1
chain C region (IGHG1), Ig gamma-2 chain C region
(IGHG2), Kininogen 1 (KNG1), Leucine-rich alpha-2-
glycoprotein (LRG), Plasma protease C1 inhibitor (SERP-
ING1), Prostaglandin D2 synthase 21kDa (PTGDS), Trans-
ferrin (TF), Trypstatin (AMBP), Uromodulin (UMOD), and
Zinc-alpha-2-glycoprotein (AZGP1). Following correction
for multiple comparisons, diﬀerential expression remained
signiﬁcant in 12 proteins (APOD, ORM1, FETUA, E9KL23,
LGALS3BP,GOLPH2,HP,KNG1,LRG,SERPING1,PTGDS,
AZGP1). Incidentally, not all unique proteins to CKD or
healthy control groups had statistically signiﬁcant up- or
down-regulation. For example, lumican was not isolated in
any healthy control subjects and was found in only three
of the six CKD subjects. Thus, lumican is unique to CKD;
however, as it was only seen in three CKD subjects, it was not
signiﬁcantly upregulated in CKD via nonparametric testing.
3.4. Gene Ontology Analysis Reveals Enrichment for Distinct
Biological Functions of Diﬀerentially Expressed Urinary Gly-
coproteins. The 23 proteins with diﬀerential expression
in CKD were subjected to a GO Database search and
further analyzed with GO Tools [20, 21]. GO Term Find-
er (http://go.princeton.edu/cgi-bin/GOTermFinder) allowed
for clustered identiﬁcation of proteins annotated to spe-
ciﬁc GO biological process, location, and function clas-
siﬁcations. A subsequent GO Term Mapper (http://go.prin-
ceton.edu/cgi-bin/GOTermMapper) analysis of signiﬁ-
cantly altered proteins was performed to bin the
proteins to GO parent terms or GO Slim terms (http://
www.geneontology.org/GO.slims.shtml).
GO analysis (Figure 3) for biological processes demon-
strated that 16 of the 23 proteins were linked to
immune/stress response and biological process regulation
(P<1 × 10
−4). 9 of the 23 were acute-phase and
inﬂammatory response proteins (P<1 × 10
−3). Six proteins
were regulators of hemostasis, platelet degranulation and
coagulation (P<1 × 10
−4), and 10 were involved inInternational Journal of Proteomics 11
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Figure 3: Global view of biological processes of diﬀerentially expressed urinary glycoproteins in CKD. Urinary glycoproteins that
were diﬀerentially detected in CKD subjects were associated with biological functions using GO process annotations. This approach
demonstrated signiﬁcant overrepresentation of proteins involved in several categories, including regulation of response to stress, platelet
activation/hemostasis/coagulation, acute-phaseresponse,regulationofbiological processes,localization, secretion,transport,andcelldeath.
Abipartitenetwork(generatedusingCytoscape[24])showingtherelationshipbetweenGOprocessannotations(yellowhexagonnodes)and
diﬀerentially regulated proteins in CKD subjects (white/red/green circular nodes). The size of the GO nodes is proportional to the number
of edges (lines) that connect them to proteins. The 10 proteins that are altered with q-value of < 0.05 are depicted in red (up-regulation)
and green (down-regulation) in CKD subjects. GAA, 70kDa lysosomal alpha-glucosidase; APOD, Apolipoprotein D; FETUA: Alpha-2-
HS-glycoprotein chain B; ORM1, Alpha-1-acid glycoprotein 1; SERPINC1, Antithrombin-III; GLB1, Beta-galactosidase; CP, Ceruloplasmin;
CUBN,Cubilin;EGF,Epidermalgrowthfactor;E9KL23,EpididymissecretoryspermbindingproteinLi44a;LGALS3BP,Galectin-3-binding
protein; GOLPH2, Golgi phosphoprotein 2; HP, Haptoglobin beta chain; IGHG1, Ig gamma-1 chain C region; IGHG2, Ig gamma-2 chain C
region; KNG1, Kininogen 1; LRG, Leucine-rich alpha-2-glycoprotein; SERPING1,Plasma protease C1 inhibitor; PTGDS, Prostaglandin D2
synthase 21kDa; TF, Transferrin; AMBP, Trypstatin; UMOD, Uromodulin; AZGP1, Zinc-alpha-2-glycoprotein.12 International Journal of Proteomics
Table 4: Diﬀerentially regulated proteins identiﬁed in CKD subjects.
Protein Code Name of the protein identiﬁed P value q-value Direction of change in CKD subjects
APOD Apolipoprotein D 0.0022 0.0224 Up
FETUA Alpha-2-HS-glycoprotein chain B 0.0022 0.0224 Up
ORM1 Alpha-1-acid glycoprotein 1 0.0022 0.0224 Up
E9KL23 Epididymis secretory sperm binding protein Li 44a 0.0022 0.0224 Up
LGALS3BP Galectin-3-binding protein 0.0022 0.022 Up
GOLPH2 Golgi phosphoprotein 2 0.0022 0.0224 Down
HP Haptoglobin beta chain 0.0022 0.0224 Up
KNG1 Kininogen 1 0.0022 0.0224 Up
LRG Leucine-rich alpha-2-glycoprotein 0.0022 0.0224 Up
SERPING1 Plasma protease C1 inhibitor 0.0022 0.0224 Up
PTGDS Prostaglandin D2 synthase 21kDa 0.0022 0.0224 Up
AZGP1 Zinc-alpha-2-glycoprotein 0.0022 0.0224 Up
GAA 70kDa lysosomal alpha-glucosidase 0.0152 0.13 Down
SERPINC1 Antithrombin-III 0.0152 0.103 Up
GLB1 Beta-galactosidase 0.0152 0.103 Down
CUBN Cubilin 0.0152 0.103 Down
EGF Epidermal growth factor 0.0152 0.13 Down
UMOD Uromodulin 0.0152 0.103 Up
TF Transferrin 0.0216 0.1387 Up
AMBP Trypstatin 0.0411 0.18 Up
CP Ceruloplasmin 0.0433 0.18 Up
IGHG1 Ig gamma-1 chain C region 0.0433 0.18 Up
IGHG2 Ig gamma-2 chain C region 0.0433 0.18 Up
localization, transport, and secretion (P<1 × 10
−4).
Other processes involved include metal ion homeostasis (4
proteins) and cell death (3 proteins).
Table 5 displays function and location for the 23 proteins
which were diﬀerentially expressed in CKD. 18 out of the
23 proteins localized to the extracellular region consistent
with possible extracellular matrix remodeling that typiﬁes
renal disease. The analysis also revealed 2 major clusters
of molecular function: 20 out of the 23 proteins were
involved in binding and protein-protein interactions (P =
5 × 10
−4). 5 proteins were endopeptidase inhibitors (P<
1 × 10
−6). Collectively, these observations implicate the
inﬂammatory/acute-phase response and extracellular matrix
remodeling in CKD. They also strongly support the proposal
that glycoproteomic analysis of urine might reveal mecha-
nisms underpinning CKD.
4. Discussion
CKD is a growing public health problem with dramatic
increases in morbidity and mortality following progression
to ESRD. Given this, there is a tremendous need for the
development of biomarkers to predict CKD progression and
allow for early therapeutic intervention. Urine proteomic
strategies are now at the forefront of this search due to
the sensitivity of MS/MS analysis and the ability to develop
noninvasive biomarkers from a readily available bioﬂuid.
Signiﬁcant progress has been made, particularly in diabetes,
where urine proteomic analysis can predict nephropathy
[6, 25, 26]. Despite these developments, the majority of
proteomic studies have relied on two-dimensional (2D)
diﬀerential in-gel electrophoresis for protein separation.
Resulting samples, particularly in CKD subjects, contain
large amounts of highly abundant plasma proteins due
to nonspeciﬁc leakage through the glomerular ﬁltration
barrier. Targeted analyses of low-abundance proteins will
likely lead to more disease-speciﬁc and clinically relevant
protein biomarkers.
We therefore focused our attention on the urinary
N-linked glycoproteome. Glycoproteins are an important
protein subfraction accounting for up to 50% of the
h u m a np r o t e o m ea ta n yg i v e nt i m e[ 27]. Due to their
critical role in cell-cell interactions and signaling cascades,
glycoproteins are promising markers for identifying kidney
disease activity and progression. In this study we present an
initial examination of the urinary N-linked glycoproteome
in CKD subjects compared to healthy control subjects.
We successfully isolated N-linked glycoproteins from twelve
urine samples utilizing a hydrazide capture technique. 122
unique glycosylated proteins were detected amongst the
twelve subjects (Table 3). This number is similar to other
recent glycoproteome analyses. Ahn et al. recently reported
isolating 164–174 unique proteins from human diabetic
plasma using a multi-lectin column enrichment technique
[16]. Yang et al. isolated 265 urinary glycoproteins from
bladder cancer subjects and healthy controls also utilizing
a multi-lectin column for enrichment, but larger sample
sizes were used than in our current study [15]. TheseInternational Journal of Proteomics 13
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results support a successful hydrazide based technique for
glycoprotein isolation in human urine. Further studies are
required to identify optimal extraction strategies.
We detected 8 glycoproteins unique to CKD subjects
and 35 unique to healthy controls (Table 2). Additionally,
of the 122 total proteins identiﬁed, 23 glycoproteins were
diﬀerentially expressed in CKD subjects versus healthy
controls. 18 were upregulated in CKD while 5 were down-
regulated (Table 4). Many of the diﬀerentially expressed
proteins have been previously linked to kidney disease
supporting a potential role as a CKD biomarker. Two of
the most signiﬁcantly upregulated proteins in our CKD
samples were AZGP1 and LRG, both of which are established
inﬂammatory mediators. Alteration of AZGP1 and LRG
expression is predictive of acute kidney injury in postsurgical
patients [28]. AZGP1 has also been shown to be increased in
diabetesanddiabeticnephropathy[13,29].PTGDS,aknown
extracellular transporter for lipophilic molecules, is formed
de novo in renal tubules [30]. PTGDS is upregulated in early
diabetes[31]andisamarkerofhypertensionandlatentrenal
injury [32]. SERPING1, an extracellular matrix regulator, is
increasedinacuterenalallograftrejectionperhapssuggesting
an important role for collagen remodeling [33]. KNG1, a
bradykinin precursor, has also been shown to be upregulated
in acute renal allograft rejection [34], and gene variation
induces altered aldosterone sensitivity in hypertensive sub-
jects [35]. Interestingly, LUM, a proteoglycan, is a protein
unique to CKD but without statistically signiﬁcant up-
regulation. Altered regulation of LUM has been linked
with abnormal collagen ﬁbril morphology as a mediator of
ﬁbrotic disease in diabetic nephropathy [36, 37]. CUBN,
an apical protein in proximal tubule cells, was unique and
downregulated in CKD. Recent investigation supports a role
of CUBN in albumin reabsorption with genetic variance at
this locus predicting microalbuminuria [38]. The decreased
urinary CUBN excretion found in our CKD population may
represent a dysfunctional variant or potentially a causative
factor responsible for increasing proteinuria.
We used annotations by the GO Consortium and GO
Tools to connect the complex array of proteins identiﬁed
in CKD subjects to biological processes, protein function,
and cellular location. Many of the multiprotein pathways
diﬀe r e n t i a l l ye x p r e s s e di nC K Da r ei n v o l v e di nc o a g u l a t i o n ,
inﬂammation, and acute-phase response (Table 5, Figure 3).
Twenty proteins were linked to protein-protein interactions
and binding. Remarkably, there were altered levels of
proteins that were involved in acute-phase response and
immune/stress response proteins (18 out of 23), implicating
a possible mechanistic role for these pathways in CKD. Our
detection of the several extracellular proteins and matrix
remodeling proteases likely reﬂects matrix remodeling that
occurs in CKD. These ﬁndings are consistent with previous
literature, as CKD is known to have increased propensity
for atherosclerosis, endothelial dysfunction, increased basal
inﬂammation, and altered stress response [39, 40].
In this study, we have established normalization tech-
niques which will be essential to future urine glycoproteome
analyses. To account for variations in the glycoprotein
extraction eﬃciency of individual samples, yeast invertase
(yeast glycoprotein with several glycopeptides) was added to
each sample prior to extraction. In this way, glycopeptides
derived from invertase serve as an internal marker for the
extraction eﬃciency in each sample. Our samples were
also normalized for urine creatinine content. This is of
particular importance as marked intersubject variability can
exist in creatinine excretion in random urine specimens
consistent with diﬀerent concentrations due to hydration
status. Indeed, such normalization would be essential to
extrapolate net excretion rates of a given protein in 24 hours
and is commonly employed in clinical practice to quantify
albumin excretion rates [23].
In summary, we have utilized a hydrazide-based
approach to enrich the urinary glycoproteome with subse-
quent identiﬁcation of the urinary glycoproteins in a human
CKD population for the ﬁrst time. Our results indicate
that urine carries a distinct population of glycoproteins that
function in proteinase inhibition, protein binding, and the
acute-phase/immune-stress response in subjects with CKD.
It will be of interest to study a larger number of subjects to
determine whether urinary levels of these proteins might be
useful indicators of CKD and to investigate the proposal that
these proteins could be markers of disease progression.
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